iCardio.ai, an AI startup based in Los Angeles and co-founded by a cardiologist, has received approval from the U.S. Food and Drug Administration (FDA) for its EchoMeasure software. This software helps doctors evaluate echocardiography (heart ultrasound) data. It marks the company’s first FDA approval, even though iCardio.ai has already been working with many healthcare partners.
According to the company, this approval is an important step for future developments. It will support new algorithms aimed at detecting heart problems, such as structural heart disease and valvular heart disease. These algorithms have already attracted interest from hospitals and heart valve makers.
iCardio.ai was founded by Joseph Sokol, a serial entrepreneur, Dr. Aakriti Gupta, a cardiologist, and Dr. Roman Sandler, an experienced industry professional.
A Busy Year for iCardio.ai
2024 has been a big year for the company. iCardio.ai announced partnerships with companies like Viz.ai, SARC MedIQ, and Abbott, and also joined the Cedars-Sinai Accelerator program in September. This program provides funding and access to experts in the healthcare field.
The partnership with Abbott, announced in September, focuses on using iCardio.ai’s technology to analyze heart ultrasound images taken with Abbott’s catheters.
“We are excited to collaborate with Abbott, a well-known global healthcare company,” said Sokol. “This partnership aligns with our mission to bring AI technology to ultrasound.”
Source: cardiovascularbusiness
